Congestive heart failure commonly called as heart failure is a medical condition that affects pumping ability of heart muscle. Certain medical conditions such as narrowing of arteries of the heart or high blood pressure gradually makes the heart too weak and stiff to fill and pump efficiently. Some symptoms of heart failure are shortness of breath while lying down or while exerting yourself, weakness, fatigue, swelling in legs, feet and ankles, irregular and rapid heartbeat, decrease in ability to exercise, persistent cough or wheezing with pink or white blood tinged phlegm, increased urination at night, swelling of abdomen, rapid weight gain due to fluid retention, lack of appetite, nausea, difficulty in concentrating, decreased alertness, severe shortness of breath and coughing up pink, and foamy mucus. There are four types of heart failure left-sided heart failure, right-sided heart failure, systolic heart failure and diastolic heart failure. Risk factors that can cause heart failure are high blood pressure, coronary artery disease, diabetes, sleep apnea, obesity, virus, alcohol use, hypertension and irregular heartbeat. Lifestyle changes can help in prevention of heart failure by reducing and managing stress, maintaining a healthy weight, eating healthy food, staying physically fit and active, controlling blood pressure, and diabetes.

Request for Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/1839

Congestive Heart Failure Drugs Market Drivers:-
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these drugs are used to treat congestive heart failure. Tolvaptan sponsored by Otsuka pharmaceuticals Co., Ltd was in phase 3 clinical trials in 2016, this drug is indicated for treatment of heart failure in children.

Approval of new drugs from Food and Drug Administration (FDA) is also expected to fuel growth of the congestive heart failure drugs market. In 2016, FDA approved Byvalson by Allergan an Ireland-based company, this drug is used for treatment of hypertension. In 2015, FDA approved Corlanor (ivabradine) by Amgen Inc. a U.S.-based company, this drug treats chronic heart failure. Furthermore, increasing number of geriatric population, unhealthy lifestyle, and increasing awareness regarding treatment of chronic disorders are driving the congestive heart failure drugs market growth.
Low awareness and diagnosis rate for the disease such as hypertension which is major cause of heart failure is primary restraint in global congestive heart failure drugs market. According to a study published in NCBI in 2013, only 49% of patients suffering from hypertension were aware of the diagnosis in high-income countries, and this percentage (i.e. 40.8%) was even lower in low-income countries.

Congestive Heart Failure Drugs Market Regional Analysis:-
North America is expected to hold dominant position in congestive heart failure drugs market due to new product launches and mergers and acquisitions. For instance, in 2015, Amgen Inc. a U.S.-based company acquired Dezima Pharma, a Netherlands based company to expand its cardiovascular drug portfolio by adding cholesterol lowering drug TA-8995 to its portfolio. TA-8995 is a cholesterol lowering drug. Moreover, Europe congestive heart failure drugs market is expected to witness significant growth due to launch of new drugs to treat chronic diseases, which prevent heart failures. For instance, Novartis AG launched a drug named Entresto in 2016, in UK. Entresto is used to treat heart failure with minimum ejection fraction (measurement of percentage of blood leaving heart each time it contracts), it is an angiotensin receptor-neprilysin inhibitor. Moreover, high prevalence of cardiovascular diseases in Asia Pacific is expected to support the growth of congestive heart failure drugs market in this region. According to a study conducted by All India Institute of Medical Science (AIIMS) and Indian Council of Medical Research (ICMR) in 2016, India’s younger population i.e. below 30 years of age are at a higher risk of developing cardiovascular diseases due to unhealthy lifestyle, alcohol consumption, and tobacco consumption,.

Congestive Heart Failure Drugs Market Key Players:-
Key players operating in congestive heart failure drugs market include Amgen Inc, Novartis AG, Astra Zeneca Plc., Bayer AG, Gilead Sciences Inc, Glaxo Smith Kline, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

LIMITED TIME OFFER - Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code "CMIFIRST1000" And Get Instant Discount Of USD 1000
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/1839

Congestive Heart Failure Drugs Market Taxonomy:-
By Drug:-
• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone antagonists
• Inotropes
• Others
By Distribution Channel:-
• Hospitals
• Retail Pharmacies
• Online Pharmacies
By Region:-
• North America
• Europe
• Latin America
• Asia Pacific
• Middle East
• Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]